306 related articles for article (PubMed ID: 29160210)
1. Exceptional response to brivaracetam in a patient with refractory idiopathic generalized epilepsy and absence seizures.
Grande-Martín A; Sopelana-Garay D; Pardal-Fernández JM; Sánchez-Honrubia RM; Sánchez-Larsen ÁA
Epileptic Disord; 2018 Feb; 20(1):60-64. PubMed ID: 29160210
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
[TBL] [Abstract][Full Text] [Related]
4. Sultiame revisited: treatment of refractory absence seizures.
Gorman KM; Shahwan A
Epileptic Disord; 2016 Sep; 18(3):329-33. PubMed ID: 27502446
[TBL] [Abstract][Full Text] [Related]
5. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.
Strzelczyk A; Klein KM; Willems LM; Rosenow F; Bauer S
Expert Rev Clin Pharmacol; 2016; 9(5):637-45. PubMed ID: 26891946
[TBL] [Abstract][Full Text] [Related]
6. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of brivaracetam: a new drug to treat epilepsy.
Milovanović JR; Janković SM; Pejčić A; Milosavljević M; Opančina V; Radonjić V; Protrka Z; Kostić M
Expert Opin Pharmacother; 2017 Sep; 18(13):1381-1389. PubMed ID: 28737479
[TBL] [Abstract][Full Text] [Related]
8. Brivaracetam add-on for refractory focal epilepsy: A systematic review and meta-analysis.
Lattanzi S; Cagnetti C; Foschi N; Provinciali L; Silvestrini M
Neurology; 2016 Apr; 86(14):1344-1352. PubMed ID: 26944275
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.
Trinka E; Tsong W; Toupin S; Patten A; Wilson K; Isojarvi J; James D
Epilepsy Res; 2020 Oct; 166():106403. PubMed ID: 32673969
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Rosenfeld WE; Benbadis S; Edrich P; Tassinari CA; Hirsch E
Epilepsy Res; 2009 Jul; 85(1):72-80. PubMed ID: 19327967
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Rufinamide in the Treatment of Idiopathic Generalized Epilepsy With Atypical Evolution: Case Report and Review of the Literature.
Albini M; Morano A; Fanella M; Lapenta L; Casciato S; Fattouch J; Manfredi M; Giallonardo AT; Di Bonaventura C
Clin EEG Neurosci; 2016 Apr; 47(2):162-6. PubMed ID: 25420625
[TBL] [Abstract][Full Text] [Related]
12. Brivaracetam for the treatment of epilepsy.
Klein P; Tyrlikova I; Brazdil M; Rektor I
Expert Opin Pharmacother; 2016; 17(2):283-95. PubMed ID: 26760311
[TBL] [Abstract][Full Text] [Related]
13. Lamotrigine in absence and primary generalized epilepsies.
Mikati MA; Holmes GL
J Child Neurol; 1997 Nov; 12 Suppl 1():S29-37. PubMed ID: 9429128
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study.
Gericke CA; Picard F; de Saint-Martin A; Strumia S; Marescaux C; Hirsch E
Epileptic Disord; 1999 Sep; 1(3):159-65. PubMed ID: 10937148
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Brivaracetam in Pediatric Refractory Epilepsy: A Single-Center Clinical Experience.
McGuire S; Silva G; Lal D; Khurana DS; Legido A; Hasbani D; Carvalho KS; Melvin J; Valencia I
J Child Neurol; 2020 Feb; 35(2):102-105. PubMed ID: 31617449
[TBL] [Abstract][Full Text] [Related]
17. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
[TBL] [Abstract][Full Text] [Related]
18. Neural Networks in Generalized Epilepsy and Novel Antiepileptic Drugs.
Werner FM; Coveñas R
Curr Pharm Des; 2019; 25(4):396-400. PubMed ID: 30892153
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in patients with refractory idiopathic generalized epilepsy.
Gomez-Ibañez A; McLachlan RS; Mirsattari SM; Diosy DC; Burneo JG
Epilepsy Res; 2017 Feb; 130():69-73. PubMed ID: 28157601
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic approach to difficult-to-treat typical absences and related epilepsy syndromes.
Mastroianni G; Ascoli M; Gasparini S; Brigo F; Cianci V; Neri S; Russo E; Aguglia U; Ferlazzo E
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1427-1433. PubMed ID: 34289757
[No Abstract] [Full Text] [Related]
[Next] [New Search]
